Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
A Randomized Phase II Study of Single Agent Erlotinib [Tarceva (TM), OSI-774] Versus Standard Chemotherapy in Patients With Previously Untreated Advanced NSCLC and a Poor Performance Status
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Greenbrae, California, United States, 94904
- California Cancer Care, Inc.
-
San Diego, California, United States, 92123
- Sharp Clinical Oncology Research
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33308
- Holy Cross Hospital
-
Miami, Florida, United States, 33136
- University of Miami
-
Miami Beach, Florida, United States, 33140
- Mount Sinai Cancer Center
-
-
Illinois
-
Evanston, Illinois, United States, 60201
- Evanston Northwestern Healthcare
-
Peoria, Illinois, United States, 61615
- Oncology/Hematology Associates of Central Illinois
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Norton Healthcare, Inc.
-
-
Maryland
-
Baltimore, Maryland, United States, 21237
- Maryland Hematology/Oncology Associates
-
-
Nevada
-
Reno, Nevada, United States, 89502
- VA Sierra Nevada Health Care System
-
-
New York
-
New York, New York, United States, 10021
- Weill Medical College of Cornell University
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58503
- FEK Addo, PC
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Gabrail Cancer Center
-
Cleveland, Ohio, United States, 44106
- University Hospitals of Cleveland
-
Columbus, Ohio, United States, 43210-1240
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
-
South Carolina
-
Charleston, South Carolina, United States, 29403
- Charleston Hematology Oncology
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- East Tennessee Oncology/Hematology, PC
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Stage IIIB or IV Nonsmall cell lung cancer (NSCLC)
- No prior chemotherapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status 2
- Clinically or radiologically measurable disease per RECIST criteria
Exclusion Criteria:
- Gastro-intestinal abnormalities
- Any concurrent anticancer therapy
- Prior treatment with epidermal growth factor receptor (EGFR) inhibitors of any kind
- Other active malignancies
- Uncontrolled brain metastases
- Severe abnormalities of the cornea
- Significant cardiac disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Erlotinib
Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
|
Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
|
|
Active Comparator: Standard Chemotherapy
Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
|
Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free Survival
Time Frame: Until time of disease progression (maximum 5 months)
|
Median time until disease progression.
Disease progression defined as radiological and/or symptomatic disease progression or death in absence of progression.
|
Until time of disease progression (maximum 5 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: From first study treatment until time of death (maximum 26.8 months)
|
Median number of months from first study treatment until time of death
|
From first study treatment until time of death (maximum 26.8 months)
|
|
Best Tumor Response
Time Frame: While receiving study treatment (maximum 60 weeks)
|
Change in size of tumor: Complete Response (CR) = no measurable tumor; Partial Response (PR) = 30% decrease in size of measurable tumor; Stable Disease (SD) = measurable tumor size has not changed; Progressive Disease (PD) = measurable tumor 20% larger than at baseline.
|
While receiving study treatment (maximum 60 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Protein Kinase Inhibitors
- Carboplatin
- Paclitaxel
- Erlotinib Hydrochloride
Other Study ID Numbers
Other Study ID Numbers
- OSI-774-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.